Joseah Biopharma

Joseah Biopharma is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the discovery and development of innovative small molecule drugs and protein degraders. The company focuses on the Ubiquitin-Proteasome System (UPS) to address unmet medical needs in oncology and autoimmune diseases. Its lead programs include highly selective USP7 inhibitors and next-generation PROTAC molecules targeting hormone receptors. Joseah Biopharma leverages its proprietary drug discovery platform to develop a robust pipeline of first-in-class and best-in-class therapies for solid tumors and hematological malignancies.